Výsledky vyhledávání - "Stephanie Clisant Delaine"

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

Autor: Antoine Adenis, Stephanie Clisant Delaine, Ludovic Evesque, Julien Fraisse, Brice Pastor, Marc Ychou, Caroline Mollevi, François Ghiringhelli, Thibault Mazard, Patrick Chalbos

Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.564. ⟨10.1186/s12885-021-08312-7⟩

Background The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer do not benefit the same from t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e1e386b78e9383b847fdecd6b8ec971
https://doaj.org/article/17e448b14f574e0c99aced3091049c7c

Zobrazit plný text záznamu

REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis

Autor: Nicolas Penel, Stephanie Clisant-Delaine, Sophie Taïeb, Antoine Italiano, Jean-Yves Blay, Vincent Berry, Emilie Decoupigny, François Bertucci, Christine Chevreau, Jennifer Wallet, Axel Le Cesne, Emmanuelle Tresch-Bruneel, Bernadette Liegl-Antzager, Thomas Brodowicz, Laurent Basson, Emilie Bogart, Olivier Mir

Publikováno v: Cancer. 123:2294-2302

BACKGROUND: In a placebo-controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression-free survival (PFS) for patients with doxorubicin-pretreated advanced nonadipocytic sarcoma. A quality-adjuste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2a1fcefd5644bbeb95bfb9dd3c37660
https://doi.org/10.1002/cncr.30661

Zobrazit plný text záznamu

Paclitaxel once weekly (wP) combined with fixed dose of oral metronomic cyclophosphamide (OMC): A dose-escalating phase I trial

Autor: Eric Dansin, Nicolas Penel, Nuria Kotecki, Emmanuelle Tresch-Bruneel, Stephanie Clisant Delaine, Marie-Cécile Le Deley, Emilie Bogart, Thomas Ryckewaert, Emilie Decoupigny, Diane Pannier, Farid El Hajbi, Sandrine Ducornet, A. Lesoin, Antoine Adenis, Luc Ceugnart, Marie Vanseymortier, Geraldine Lauridant Philippin

Publikováno v: Journal of Clinical Oncology. 35:e14015-e14015

e14015 Background: OMC, as continuous administration of low doses of chemotherapy acts as direct cytotoxic as well as antiangiogenetic agent. wP also induces antiangiogenic effects in mouse models. The aims of this trial were to determine the recomme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74733f1f9ed9eacebf5160b796447ff9
https://doi.org/10.1200/jco.2017.35.15_suppl.e14015

Zobrazit plný text záznamu

Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial

Publikováno v: Journal of Clinical Oncology. 35:737-737

737 Background: A is approved in combination with FOLFIRI (A-FOLFIRI) for the treatment of mCRC patients (pts) previously treated with oxaliplatin. PULSAR trial (NCT02173990) aims to measure the activity A-FOLFIRI as 1st-line mCRC treatment. Key seco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2a0813884f63c709ddbf740c88d8b78
https://doi.org/10.1200/jco.2017.35.4_suppl.737

Zobrazit plný text záznamu

Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial

Publikováno v: Journal of Clinical Oncology. 34:11003-11003

11003Background: We investigated the activity and safety of RE in doxorubicin-pretreated metastatic soft tissue sarcomas (STS). Methods: REGOSARC (NCT01900743) consisted of 4 independent cohorts of...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edc7fef47c81d40b818b705c89db5dd3
https://doi.org/10.1200/jco.2016.34.15_suppl.11003

Zobrazit plný text záznamu

Discontinuation of first-line chemotherapy (CT) after 6 weeks of CT in patients (pts) with metastatic squamous-cell esophageal cancer (MSEC): A randomized phase II trial

Publikováno v: Journal of Clinical Oncology. 34:4002-4002

4002Background: Even though there is no evidence to support the use of CT in MSEC, many physicians treat pts with good ECOG performance status (PS) with fluorouracil (5FU)/platinum-based CT. Theref...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51b88a66a322d77b27cf02b48f5f3b5c
https://doi.org/10.1200/jco.2016.34.15_suppl.4002

Zobrazit plný text záznamu

A phase II trial of sorafenib (SO) in advanced chordoma patients (pt)

Autor: Jean-Yves Blay, Esma Saada, Damien Vansteene, Julien Domont, François Bertucci, Sophie Piperno-Neumann, Nicolas Penel, Axel Le Cesne, Olivier Collard, Stephanie Clisant Delaine, Emmanuelle Tresch, Antoine Italiano, Eric Yaovi Amela, Christine Chevreau, Nicolas Isambert, Sébastien Salas, Emmanuelle Bompas

Publikováno v: ResearcherID

10520 Background: To report in a hypothesis-generating phase II study the activity and safety of SO in advanced chordomas. Methods: Pts received SO 800 mg/d until progression, intolerance or up to ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a686579ef7a448a4aa2ee364cc05da10
https://doi.org/10.1200/jco.2015.33.15_suppl.10520

Zobrazit plný text záznamu

Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a doubleblind, randomized placebo (PL) controlled phase II trial

Publikováno v: ResearcherID

10504 Background: RE is a multikinase inhibitor that has demonstrated activity in gastrointestinal stromal tumors. We investigated its activity and safety in anthracycline pretreated metastatic sof...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371917f8f4bdf3384aa20a5981861266
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358036900138&KeyUID=WOS:000358036900138

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání